Jay Bradner (Jeff Rumans for Endpoints News)
Novartis partners with the Gates Foundation on one of the Holy Grails in gene therapy: a simple, in vivo approach to curing sickle cell disease
Having helped usher in a “new era” of sickle cell disease treatment with Adakveo, Novartis has set its sights on an even higher goal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
